Data from clinicaltrials.gov - Curated by EPG Health - Last updated 10 January 2020

NanoPac is very small (submicron) particles of the chemotherapy drug, paclitaxel, which is administered intravenously in a number of types of cancer. These submicron particles are injected directly into solid tumors to target cancer at...

purpose

Brief Summary:
This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.

Detailed Description:
NanoPac is very small (submicron) particles of the chemotherapy drug, paclitaxel, which is administered intravenously in a number of types of cancer. These submicron particles are injected directly into solid tumors to target cancer at the site of disease with less systemic exposure than intravenously administered chemotherapy. In this study, this submicron particle paclitaxel will be injected directly into the prostate lesion in men with prostate cancer scheduled for prostatectomy on up to three different occasions. All subjects in the study will receive NanoPac and will be evaluated to see if NanoPac is safe, well-tolerated, and has an impact on prostate cancer.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 18 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Open-label, single group, safety, efficacy, and pharmacokinetic study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Trial of NanoPac Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy
Estimated Study Start Date: March 2020
Estimated Primary Completion Date: December 2021
Estimated Study Completion Date: January 2022

Arm:
- Experimental:
NanoPac

Category Value
Date last updated at source 08-Jan-20
Study type(s) Interventional
Expected enrolment 18
Study start date 01-Mar-20
Estimated primary completion date 01-Dec-21

View full details

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Related Content